BTK
Gli inibitori della tirosina chinasi di Bruton (BTK) sono composti che mirano specificamente a inibire la BTK, un enzima cruciale coinvolto nella segnalazione del recettore delle cellule B e nella regolazione dell'angiogenesi. La BTK svolge un ruolo significativo nella proliferazione e nella sopravvivenza delle cellule cancerose, in particolare nelle malignità ematologiche. Inibendo la BTK, questi composti possono interrompere l'angiogenesi e la crescita tumorale, rendendoli preziosi nella terapia del cancro. Presso CymitQuimica, offriamo una gamma di inibitori della BTK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 169 prodotti per "BTK".
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purezza:99.89%Colore e forma:SolidPeso molecolare:502.56BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formula:C23H22FN5O3Colore e forma:SolidPeso molecolare:435.45BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formula:C35H35ClN4O3SColore e forma:SolidPeso molecolare:627.2GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formula:C30H32N10O2Colore e forma:SolidPeso molecolare:564.64UBX-382
CAS:UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Formula:C42H44N10O4Colore e forma:SolidPeso molecolare:752.86JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColore e forma:SolidPeso molecolare:440.93BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Formula:C27H26F2N4O2Colore e forma:SolidPeso molecolare:476.52WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formula:C26H22FN9O2Colore e forma:SolidPeso molecolare:511.51BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Colore e forma:SolidPeso molecolare:587.45BTK degrader-1 intermediate
CAS:BTKdegrader-1 intermediate (compound 5) is a precursor in the synthesis of BTKdegrader-1, which serves as a toxin for Antibody-drug Conjugates (ADC) used in developing related molecules.Formula:C40H44F2N6O2Colore e forma:SolidPeso molecolare:678.81CFON-026
CAS:CFON-026 is a selective, orally active, non-covalent BTK inhibitor with an IC50 of 0.27 nM. It demonstrates significant antitumor activity against wild-type BTK (TMD8 and REC-1) as well as all clinically relevant BTK resistance mutations (BTKC481S, T474I, L528W, and V416L). CFON-026 induces complete tumor regression in the TMD8 xenograft mouse model. This compound is applicable for research into hematologic cancers, such as chronic lymphocytic leukemia and Waldenström's macroglobulinemia.Formula:C33H34N8O2Peso molecolare:574.68RET-IN-14
CAS:RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formula:C24H23FN8O4Colore e forma:SolidPeso molecolare:506.49BIIB129
CAS:BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.Formula:C19H22N6O2Purezza:98.11%Colore e forma:Yellow SolidPeso molecolare:366.42BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formula:C26H36N6O3Colore e forma:SolidPeso molecolare:480.6BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formula:C28H24FN5O2Colore e forma:SolidPeso molecolare:481.52Birelentinib
CAS:Birelentinib (Birelentinib) is an inhibitor of both wild-type and mutant BTK with IC₅₀ values of 6.72 and 6.11 nM, respectively.Formula:C23H21F2N5O3Purezza:99.36% - 99.78%Peso molecolare:453.44Ref: TM-T85923
5mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta1mg207,00€10mg735,00€100mg2.008,00€GDC-0834 S-enantiomer
CAS:GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).Formula:C33H36N6O3SPurezza:98%Colore e forma:SolidPeso molecolare:596.74BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formula:C25H24F2N4O2Colore e forma:SolidPeso molecolare:450.48JAK3/BTK-IN-3
CAS:JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formula:C22H28N8OColore e forma:SolidPeso molecolare:420.51BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formula:C29H25N5O4S2Colore e forma:SolidPeso molecolare:571.67
